Will Roche/Genentech team create industry model?

Roche's proposal to acquire all outstanding shares of Genentech is being viewed as a model marriage of a Big Pharma company focused on molecular diagnostics and a Big Biotech company designing new genetic therapies for an era of personalized medications.

The $43.7 billion offer is seen as a bold move by Roche's new CEO, Severin Schwan (photo). And Schwan is insisting that the offer has nothing to do with finding ways to bolster profits through cost-cutting maneuvers.

"Now is a good time to take Genentech private,'" Schwan told BusinessWeek in a telephone interview. "This transaction is about strengthening innovation; it is not about cost-cutting."  

- read the article from BusinessWeek

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.